Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

Q16552 (IL17_HUMAN) Homo sapiens (Human)

Interleukin-17A UniProtKBInterProSTRINGInteractive Modelling

155 aa; Sequence (Fasta)

Available Structures

30 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structure of the IL-17A-IL-17RA-IL-17RC ternary complex Heteromer
Q8NAC3; Q96F46;
34-154
NAG;NAG;
Assess
Structure of the IL-17A-IL-17RA binary complex Heteromer
Q96F46;
34-154
NAG;NAG;
Assess
Computationally designed functional antibody Heteromer
30-149
Assess
Crystal Structure of IL-17A/Fab6785 complex Heteromer
33-151
GOL;CL;SO4;
Assess
Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC Heteromer
Q8NAC3; Q96F46;
37-155
NAG;
Assess
Crystal Structure of Human IL-17AF Heteromer
Q96PD4;
39-153
NAG;
Assess
Structure of interleukin 17a in complex with il17ra receptor Heteromer
Q96F46;
40-154
NAG;NAG;NAG;
Assess
Crystal Structure of the 11.003 Fab in complex with human IL-17A Heteromer
41-151
GOL;
Assess
Crystal Structure of scFv CAT2200 LH in complex with IL-17A Heteromer
42-152
SO4;
Assess
Complex IL-17A/anti-IL-17A-76 Heteromer
43-153
GOL;CL;SO4;
Assess
Crystal Structure of human IL-17AF in complex with human IL-17RA Heteromer
Q96F46; Q96PD4;
44-154
NAG;NAG;
Assess
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Heteromer
45-154
63O;
Assess
Crystal Structure of spFv CAT2200 LH in complex with IL-17A Heteromer
43-151
CL;
Assess
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Heteromer
44-152
Assess
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Heteromer
45-152
63Q;
Assess
IL-17A in complex with the humanized antibody HB0017 Heteromer
43-150
MLA;ACY;
Assess
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Heteromer
44-151
Assess
Fab antigen complex Heteromer
60-155
Assess
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Heteromer
59-152
63P;
Assess
Structure of IL-17A in complex with a potent, fully human neutralising antibody Heteromer
59-151
SO4;
Assess
Fab antigen complex Heteromer
64-152
Assess
IL-17A in complex with peptidehomo-2-mer38-154
EDO;
Assess
IL17A homodimer bound to Compound 7homo-2-mer44-154
U5Q;
Assess
IL17A homodimer bound to Compound 6homo-2-mer44-153
U5X;GOL;
Assess
IL17A homodimer bound to Compound 5homo-2-mer43-152
U6C;
Assess
IL17A homodimer bound to Compound 10homo-2-mer44-152
U5I;
Assess
Human interleukin 17Ahomo-2-mer42-150
Assess
IL-17A in complex with small molecule modulatorshomo-2-mer42-150
RMK;
Assess
Crystal structure of human IL-17A cytokine in complex with macrocyclehomo-2-mer42-150
UTF;
Assess
IL-17A in complex with small molecule modulatorshomo-2-mer42-150
RMQ;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5n7w.1.Emonomer0.6730-149
100.00
Assess